Opinion
Video
Author(s):
Edward Kim, MD, MBA, describes the potential role of tyrosine kinase inhibitors (TKIs) in the treatment of patients with HER2-mutated non–small cell lung cancer.
Nivolumab Plus AVD Prolongs PFS vs Brentuximab Vedotin Plus AVD in Advanced-Stage Hodgkin Lymphoma
Patient Prioritization Is the Foundation for a Successful Neurologic Oncology Career: With D. Ross Camidge, MD, PhD; and Douglas Ney, MD
ADCs Redefine HER2+ NSCLC Landscape With Potential to Shift to the Frontline Setting
How to Apply Research Developments in ALK-Positive NSCLC: With Chandler Park, MD, and Tejas Patil, MD
Safety Data Help Affirm Adjuvant Alectinib as a New SOC in ALK+ NSCLC
Osimertinib Plus Savolitinib Generates Durable Responses in EGFR-Mutant, MET-Amplified NSCLC
RVU120 Shows Early Promise in R/R Metastatic or Advanced Solid Tumors
The WEE1 Inhibitor APR-1051 Shows Early Safety and Tolerability in Advanced, Mutated Solid Tumors
TYRA-300 Is Safe, Generates Preliminary Antitumor Activity in FGFR3+ Metastatic Urothelial Cancer
Experts Highlight Noteworthy Research From the 2024 ESMO Congress